Holdings in Company
15 June 2021
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody
discovery, engineering and supply for both therapeutic drug and
diagnostic applications, has been informed by Crescent Capital NI
Limited (“Crescent Capital”) that Crescent Capital II LP (“Crescent II”)
has distributed in specie all of its holdings in Fusion to its
underlying investors due to the fund reaching the end of its intended
lifespan. The distribution was implemented on 11 June 2021 with an
effective date of 5 June 2021. As a result, the 2,223,415 ordinary
shares of 4p each in Fusion Antibodies (“Ordinary Shares”) previously
held by Crescent II have all been transferred to Invest Northern Ireland
and Crescent II no longer holds any Ordinary Shares. Crescent
Capital III LP (“Crescent III”) still holds 613,382 Ordinary Shares,
equivalent to 2.38% of the Company’s issued share capital. Colin Walsh,
Non-Executive Director of Fusion, is Chief Executive and founder of
Crescent Capital, which is the fund manager for Crescent II and Crescent
III.
As a result of the share transfer detailed above, Invest Northern Ireland now directly holds 3,197,865 Ordinary Shares, equivalent to 12.39% of the Company’s issued share capital. In addition, Invest Northern Ireland is also indirectly interested in the 613,382 Ordinary Shares held by Crescent III and 358,850 Ordinary Shares held by Nitech Growth Fund LP.
Enquiries:
| Fusion Antibodies plc | www.fusionantibodies.com | |
| Richard Jones, Chief Executive Officer | Via Walbrook PR | |
| James Fair, Chief Financial Officer | ||
| Allenby Capital Limited | Tel: +44 (0)20 3328 5656 | |
| James Reeve (Corporate Finance) Tony Quirke (Sales and Corporate Broking) |
||
| Walbrook PR | Tel: +44 (0)20 7933 8780 fusion@walbrookpr.com | |
| Anna Dunphy | Mob: +44 (0)7876 741 001 | |
| Paul McManus | Mob: +44 (0)7980 541 893 | |
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the development
of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18
December 2017. Fusion provides a broad range of services in antibody
generation, development, production, characterisation and optimisation.
These services include antigen expression, antibody production,
purification and sequencing, antibody humanisation using Fusion's
proprietary CDRx TM platform and the
production of antibody generating stable cell lines to provide material
for use in clinical trials. Since 2012, the Company has
successfully sequenced and expressed over 250 antibodies and
successfully completed over 200 humanisation projects and has an
international, blue-chip client base, which has included eight of the
top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University
Belfast. The Company's mission is to enable pharmaceutical and
diagnostic companies to develop innovative products in a timely and
cost-effective manner for the benefit of the global healthcare industry.
Fusion Antibodies provides a broad range of services in antibody
generation, development, production, characterisation and
optimisation.
Fusion Antibodies growth strategy is based on combining the latest
technological advances with cutting edge science to deliver new
platforms that will enable Pharma and Biotech companies get to the
clinic faster, with the optimal drug candidate and ultimately speed up
the drug development process.
The global monoclonal antibody therapeutics market was valued at $135.4 billion in 2018 and is forecast to surpass $212.6 billion in 2022, an increase at a CAGR of 12.0 per cent. for the period 2018 to 2022. In 2017, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $63.2 billion.
